LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Swiss Stocks Close Lower; Nestlé Edges Down MT
SANDOZ : Berenberg no longer Buy CF
Berenberg Downgrades Sandoz to Hold MT
The mood is getting heavier, but Taylor Swift is keeping watch Our Logo
Octavian Begins Sandoz Group Coverage at Buy MT
Four steps back, one step forward Our Logo
Transcript : Sandoz Group AG Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 08:30 AM
European Midday Briefing : Europe Hit by U.S. Tech Selloff, Growth Doubts DJ
Axsome Therapeutics Reaches Agreement to Dismiss Sunosi Patent Litigation With Sandoz MT
Swiss Market Index Closes Little Changed Ahead of Key US Inflation Data MT
Sandoz: two biosimilars launched in Canada CF
Sandoz Canada Announces the Launch of Two Denosumab Biosimilar CI
Sandoz: Enzeevu approved in the United States CF
Switzerland's Sandoz Obtains US FDA Approval for Eylea Biosimilar MT
Sandoz Group AG Receives FDA Approval for Enzeevu? (Aflibercept-Abzv), Further Strengthening Us Biosimilar Position CI
Sandoz: share price rebounds, UBS raises target CF
Morningstar Upgrades Sandoz Group to Hold with Higher PT MT
SANDOZ : UBS raises its target price CF
Swiss Market Index Edges Down; GAM Shares Rise MT
Global markets live: Amazon, Intel, Boeing, Robinhood, KKR, Zillow... Our Logo
SANDOZ : H1 profitability miss; the markets now doubt that the full-year guidance can be achieved Alphavalue
Sandoz raises growth forecast for 2024 CF
Transcript : Sandoz Group AG, H1 2024 Earnings Call, Aug 08, 2024
Sandoz Group AG Reports Earnings Results for the Half Year Ended June 30, 2024 CI
Sandoz Posts Lower H1 Attributable Net Income; Total Sales Up MT
Chart Sandoz Group AG
More charts
Logo Sandoz Group AG
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.
Employees
22,633
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
41.54USD
Average target price
44.69USD
Spread / Average Target
+7.58%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. SDZ Stock
  4. News Sandoz Group AG
  5. Switzerland's Sandoz Obtains US FDA Approval for Eylea Biosimilar
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW